Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran

Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran

Tozinameran, a messenger ribonucleic acid (mRNA)-based coronavirus disease 19 (COVID-19) vaccine, has a favorable safety profile and is highly efficacious in preventing COVID-19. Adverse reactions such as pain at the vaccination site, fever, malaise, headache, rash, and anaphylaxis have been commonl...

Full description

Bibliographic Details
Main Authors:	Naohiro Oda, Reo Mitani, Ichiro Takata, Mikio Kataoka
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Respiratory Medicine Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007122000405

Similar Items

Acute exacerbation of idiopathic pulmonary fibrosis after bivalent {tozinameran and famtozinameran} mRNA COVID-19 vaccination
by: Kenji Tsumura, et al.
Published: (2023-01-01)

Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran – a clinical case and global pharmacovigilance data
by: Raphael Battegay, et al.
Published: (2021-12-01)

Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir
by: Naohiro Oda, et al.
Published: (2021-07-01)

Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
by: Rumiko Shimazawa, et al.
Published: (2021-12-01)

mRNA as a Therapeutics: Understanding mRNA Vaccines
by: Ferdi Oğuz, et al.
Published: (2022-03-01)

New insights into antibody levels against SARS-CoV-2 for healthcare personnel vaccinated with tozinameran (Comirnaty).
by: Antonio Fernández-Suárez, et al.
Published: (2022-01-01)

Excipients and mRNA vaccines
by: Shireesh Apte
Published: (2020-12-01)

mRNA-Based Vaccines
by: Frank Kowalzik, et al.
Published: (2021-04-01)

The History of mRNA Vaccine
by: Maham Akhlaq
Published: (2021-06-01)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01)

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine
by: Hyemin Chung, et al.
Published: (2022-12-01)

Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines
by: Qasim H, et al.
Published: (2023-04-01)

Severe hyponatremia with consciousness disturbance after receiving SARS-CoV-2 mRNA vaccination
by: Takuya Kumagai, et al.
Published: (2023-07-01)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01)

mRNA vaccines as cancer therapies
by: Shaoxiong Huang, et al.
Published: (2024-12-01)

Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024-12-01)

Recent Updates on mRNA Vaccines
by: Emily Sydow, et al.
Published: (2022-07-01)

mRNA Vaccines against Flaviviruses
by: Clayton J. Wollner, et al.
Published: (2021-02-01)

Neo-Antigen mRNA Vaccines
by: Arthur Esprit, et al.
Published: (2020-12-01)

mRNA Innovates the Vaccine Field
by: Norbert Pardi
Published: (2021-05-01)

The Delivery of mRNA Vaccines for Therapeutics
by: Nitika, et al.
Published: (2022-08-01)

The advances of adjuvants in mRNA vaccines
by: Chunyuan Xie, et al.
Published: (2023-10-01)

Progress and challenges of mRNA vaccines
by: Liangru Lin, et al.
Published: (2023-01-01)

mRNA vaccines for cancer immunotherapy
by: Yashavantha L. Vishweshwaraiah, et al.
Published: (2022-12-01)

Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines [Letter]
by: Ali A, et al.
Published: (2023-06-01)

Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
by: Mena Hajiaghapour Asr, et al.
Published: (2023-04-01)

Subdural hematoma due to skull base bone metastasis of epidermal growth factor receptor mutated non‐small cell lung cancer
by: Tomohiko Oka, et al.
Published: (2024-07-01)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
by: Oleguer Parés-Badell, et al.
Published: (2022-07-01)

Thyroiditis after mRNA Vaccination for COVID-19
by: Arunava Saha, et al.
Published: (2022-01-01)

Current Developments and Challenges of mRNA Vaccines
by: Chen, Jinjin, et al.
Published: (2022)

mRNA therapeutics: beyond vaccine applications
by: Bhat, Balkrishen, et al.
Published: (2022)

Will the mRNA vaccines interfere with Oneâs DNA?
by: Mohd Nordin, Musa, et al.
Published: (2021)

Antitumor mRNA vaccines based on neoantigens
by: E. V. Starostina, et al.
Published: (2025-01-01)

Combinative workflow for mRNA vaccine development
by: Renuka Khanzode, et al.
Published: (2024-09-01)

mRNA Vaccine Nanoplatforms and Innate Immunity
by: Lai Wei, et al.
Published: (2024-01-01)

Recent progress in mRNA cancer vaccines
by: Ruhui Yao, et al.
Published: (2024-12-01)

Nanomaterial Delivery Systems for mRNA Vaccines
by: Michael D. Buschmann, et al.
Published: (2021-01-01)

An Update on mRNA-Based Viral Vaccines
by: Subbiah Jeeva, et al.
Published: (2021-08-01)

Advances in mRNA-Based Cancer Vaccines
by: Ling Ni
Published: (2023-10-01)

mRNA vaccines in disease prevention and treatment
by: Gang Zhang, et al.
Published: (2023-09-01)